- ￥240 - 4830
- Solarbio
- 北京
- IV0740
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
Vesatolimod
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
1228585-88-3
- 规格：
100mg/50mg/25mg/10mg/1mg/5mg
| 规格： | 100mg | 产品价格： | ￥4830.0 |
|---|---|---|---|
| 规格： | 50mg | 产品价格： | ￥2960.0 |
| 规格： | 25mg | 产品价格： | ￥2080.0 |
| 规格： | 10mg | 产品价格： | ￥1040.0 |
| 规格： | 1mg | 产品价格： | ￥240.0 |
| 规格： | 5mg | 产品价格： | ￥540.0 |
是Toll样受体7（TLR-7）的新型有效，选择性的小分子激动剂
| 基本信息 | |
| CAS | No.1228585-88-3 |
| 中文名称 | 维沙莫德 |
| 英文名称 | Vesatolimod |
| 别名 | GS-9620 |
| 分子式 | C22H30N6O2 |
| 分子量 | 410.51 |
| 溶解性 | Soluble in DMSO ≥1mg/mL(Need ultrasonic) |
| 纯度 | ≥98% |
| 外观(性状) | White to light yellow Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| MDL | MFCD25372045 |
| SMILES | O=C1NC2=C(N)N=C(OCCCC)N=C2N(CC3=CC=CC(CN4CCCC4)=C3)C1 |
| 靶点 | Toll-like Receptor (TLR) |
| 通路 | Immunology & Inflammation |
| 背景说明 | Vesatolimod是Toll样受体7(TLR-7)的新型有效,选择性的小分子激动剂。 |
| 生物活性 | Vesatolimod (GS-9620) is a potent， selective and orally active agonist of Toll-Like Receptor (TLR7) with an EC50 of 291 nM.[1-3] |
| IC50 | EC50: 291 nM (TLR7)， 9 μM (TLR8)[3] |
| In Vitro | Vesatolimod (GS-9620) rapidly internalizes into cells and preferentially localizes to and signals from endo-lysosomal compartments. To test this hypothesis， the kinetics of cellular uptake of the compound in Daudi cells using tritiated Vesatolimod (3H-GS-9620) is measured. The kinetics of 3H-GS-9620 accumulation is rapid， reaching concentration-dependent steady-state equilibrium in approximately thirty minutes. Measured intracellular concentration of 3H-Vesatolimod is 5-fold higher than the extracellular concentration of 3H-GS-9620 used to treat cells. Increases in intracellular 3H-Vesatolimod concentrations are roughly proportional with increasing concentrations of 3H-GS-9620[1]. |
| 细胞实验 | Single oral doses of Vesatolimod (GS-9620) at 0.3 and 1 mg/kg in uninfected chimpanzees demonstrates a dose- and exposure-related induction of serum IFN-α， select cytokines/chemokines， and IFN-stimulated genes (ISG) in the peripheral blood and liver. Following oral administration at 0.3 (n=3)， and 1 mg/kg (n=3 and n=4)， Vesatolimod (GS-9620) Cmax is 3.6±3.5， 36.8±34.5， and 55.4±81.0 nM， respectively. Peak serum IFN responses occur at 8 h post-dose. The mean peak levels of induced serum IFN-α are 66 and 479 pg/mL at doses of 0.3 and 1 mg/kg， respectively. Vesatolimod (GS-9620) treatment induces ISG transcripts including ISG15， OAS-1， MX1， IP-10 (CXCL10)， and I-TAC (CXCL11) in peripheral blood mononuclear cells (PBMC) at 0.3 mg/kg and in both PBMC and the liver at 1 mg/kg[2]. |
| 细胞实验 | Daudi cells are incubated for indicated times with varying concentrations [3H]Vesatolimod (GS-9620) (0.7μCi/mL). Cell associated radioactivity is extracted with ice cold 80% ethanol and measured using liquid scintillation counting. The total amount of Vesatolimod in cells is calculated from a calibration curve for Vesatolimod (GS-9620) mass versus radioactivity. Cell volume is measured[1]. |
| 动物实验 | Chimpanzee[2] Chimpanzees are used. The trial design includes 4 weeks of pre-study evaluation (Day-28， -13 and just prior to first dose) and two cycles of oral Vesatolimod (GS-9620) treatment every other day three times per week for 4 weeks with one cycle at 1 mg/kg， and， after a one week rest， a second cycle at 2 mg/kg. Animals are also intensely monitored for 14 weeks after treatment to assess tolerability and durability of response. |
| 数据来源文献 | [1]. Rebbapragada I， et al. Molecular Determinants of GS-9620-Dependent TLR7 Activation. PLoS One. 2016 Jan 19;11(1):e0146835. [2]. Lanford RE， et al. GS-9620， an Oral Agonist of Toll-Like Receptor-7， Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees. Gastroenterology. 2013 Feb 13. pii: S0016-5085(13)00169-8. [3]. D Tumas， et al. Preclinical Characterization of GS-9620， A Potent and Selective Oral TLR7 Agonist. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验【操作步骤】6.2 分文章作者，亲手教你如何轻松搞定生信文章
通过 Results 的小标题来看一下总体套路： 1、目标基因在胶质瘤中表达增高 2、目标基因高表达能提示胶质瘤患者预后不良 3、目标基因与多种生物过程密切相关 4、目标基因作用于炎症反应和免疫应答 5、目标基因与胶质瘤患者的免疫检查位点关系密切 通过这一系列小标题，发现文章套路了吗？ 总结而言，扩展到各种肿瘤的生信研究，大致思路就是：某基因的表达情况—生存预后分析—基因通路富集—富集结果验证—结合临床应用。 总体思路有了把握，那么具体如何执行呢？ Figure 1 首先，该文章通过「http
Nature 重磅：新发脑胶质瘤疫苗初见成效，瞄准肿瘤「阿喀琉斯之踵」
，发挥抗肿瘤效应。该成果以 A vaccine targeting mutant IDH1 in newly diagnosed glioma 为题发表在最新的 Nature 上 [2]。 图片来源：Nature 研究内容：这是一项靶向 IDH1R132H 的多肽疫苗治疗 III-IV 级（WHO 分级）胶质瘤的安全性、耐受性和免疫原性的多中心 I 期临床研究（NCT02454634）。研究人员筛选了 44 名患者，其中 32 名患者入组参与了临床试验并接受了 IDH-vac 治疗。在这 32 名
在无血清细胞培养条件下将人 iPS 细胞体外分化为结肠类器官
Kevin Su , Nick Asbrock , Vic Chu, Ph.D. , Stefanie Hoffmann, M.S. , Philip Hewitt, Ph.D 类器官是一种复杂的自组织 3D 细胞培养模型，通常源自于干细胞。1类器官已报道可由多种组织产生，包括脑、2 肠、3 胃、4 结肠、5 肝脏、6 胰腺、6 肺、7 肾脏 8 和患者来源的肿瘤。9 上皮肠类器官，通常称为肠样或小肠，可维持胃肠系统的生理特征，并且已成为模拟肠道发育和疾病（包括结肠癌、乳糜泻、炎症
技术资料暂无技术资料 索取技术资料
